A short item claims a newer group of weight loss drugs beats Ozempic, without naming the drugs or the data behind the claim.
Recap by typeshit. Full story at ΕΜΥ.
The weight loss drug class started with a lizard. A short local feature looks at how the Gila monster led researchers to GLP-1 medicines.
Healio
At the Cardiometabolic Health Congress, the UAB professor asked whether maximal weight loss is optimal and flagged that most non-diabetic patients quit GLP-1s within two years.
The digital health doctor shares a take on GLP-1 therapy paired with lifestyle change and digital programs, calling the finding unsurprising.
The obesity medicine specialist told a Fall Clinical 2026 panel that sleep apnea, MASH and heart coverage can open GLP-1 access, and that retatrutide could reach market next year.
In her second month on the drug, she says the scale hasn't moved since stepping up to 5 mg and an itch has spread over her body. She asks others if they've had the same.
Bazaar looks at how the beauty business is reacting to GLP-1 side effects, from 'Ozempic face' to worries about collagen loss and loose skin.
Loading…